RSRadhika Sarda

Radhika Sarda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Radhika Sarda has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-world experience with cefepime/zidebactam under compassionate use

    by Dilip K Dubey, Subramanian Swaminathan, Praveen K Tirlangi, Vishnu Rao Polati, Rajeev Soman, Rasika Sirsat, Abdul Ghafur, Raman Gaikwad, Vasant Nagvekar, Abi S Manesh, et al.

    Introduction: Cefepime/zidebactam is a β-lactam/β-lactam enhancer combination with activity against carbapenem-resistant (CR) Gram-negative pathogens, including metallo-β-lactamase (MBL)-producing organisms. Before regulatory approval, cefepime/zidebactam was available through a compassionate-use programme for patients with CR Gram-negative infections who had limited available treatment options. Methods: We conducted a retrospective, multi-country analysis of patients who received cefepime/zidebactam through compassionate use between 2022 and 2025. Data included demographics, comorbidities, acute complications, prior antibiotic exposure, infection characteristics, microbiology, treatment details, and investigator-assessed outcomes. Results: Eighty-five patients were included (median age 48 years; 57.6% in an intensive care unit at initiation). Primary infections included pneumonia/respiratory infection (30.6%), bone and joint infection (24.7%), and complicated urinary tract infection/pyelonephritis (14.1%). Pseudomonas aeruginosa was the predominant pathogen (77.6%), followed by Klebsiella pneumoniae (14.1%) and Acinetobacter baumannii (11.8%); infections involving at least two Gram-negative pathogens occurred in 10.6%. Among isolates with available genotypic data, MBLs were common and predominantly NDM. The cefepime/zidebactam minimum inhibitory concentration (MIC)50 and MIC90 were 8 and 32 mg/L, respectively. Investigator-assessed clinical success at the end of therapy was achieved in 88.2% of patients (95% CI, 79.7–93.5), and microbiological eradication in 89.4% (95% CI, 81.1–94.3); on-therapy mortality was 10.6% (95% CI, 5.7–18.9). Treatment-emergent adverse events occurred in five patients (5.9%, 95% CI, 2.5–13.0), with one discontinuation. Conclusions: In this uncontrolled compassionate-use case series, cefepime/zidebactam treatment was accompanied by high investigator-assessed clinical success and microbiological eradication in patients with severe infections caused by CR Gram-negative pathogens. These observations require confirmation in prospective controlled studies.

  • Open Access

    Prevalence of Long COVID-19 and its Impact on Quality of Life Among Outpatients With Mild COVID-19 Disease at Tertiary Care Center in North India

    by Radhika Sarda, Arvind Kumar, Ankit Chandra, Megha Bir, Sanchit Kumar, Manish Soneja, Sanjeev Sinha, Naveet Wig

    Literature is lacking on the spectrum of symptoms of long COVID-19 (defined as symptoms persisting beyond 28 days of diagnosis) and its impact on quality of life. This single-center, cross-sectional study included mild COVID-19 cases as determined by a positive real-time reverse transcription polymerase chain reaction test. Patients were contacted at least 28 days after diagnosis and were interviewed telephonically using semi-structured questionnaires for duration of symptoms, fatigue using Fatigue Severity Scale (FSS) and quality of life using the World Health Organization Quality of Life: Brief Version (WHOQOL-BREF). A total of 251 COVID-19 patients were included; of which 169 (67.3%) were males. The mean age of the patients was 35.8 years (SD = 12.5). The prevalence of long COVID-19 was 28.2% (n = 71, 95% CI: 23.0–34.2). The most common symptoms involved the musculoskeletal system (12.7%), upper respiratory tract (7.6%), and fatigue among 17 (6.8%) patients. Patients with long COVID-19 had significantly higher FSS score and lower WHOQOL-BREF score compared to the patients without long COVID-19 (<28 days).


  • Open Access

    Impact of metabolic and cardiovascular disease on COVID-19 mortality: A systematic review and meta-analysis

    by Shubham Sahni, Gaurav Gupta, Radhika Sarda, Shivam Pandey, R.M. Pandey, Sanjeev Sinha


  • Open Access

    Impact of COVID-19 on the patients' income and work in Delhi, India

    by Ankit Chandra, Radhika Sarda, Arvind Kumar, Megha Bir, Pragyan Paramita Parija, Aishee Pal, Sanjeev Sinha, Vikas H, Naveet Wig

    Background: Currently, there is no data on the impact of COVID-19 on patients' income and work in India. Methods: We conducted a cross-sectional study at a tertiary hospital in New Delhi. We included all the patients who were ≥18 years of age and consecutively diagnosed with COVID-19 between the 1st of May 2020 to 31st July 2020. Patients were interviewed by a physician using a semi-structure questionnaire. Data were collected on socio-economic status, occupation, income loss, leaves taken, decrease in work efficiency (self-perceived) and about-facing any stigma/discrimination at the workplace. Results: Out of 245 patients, 190 patients were employed. A total of 126 patients (66.3%) self-reported their work was affected due to COVID-19 disease. A total of 30.5% of patients (n = 58/190) reported deduction in their salary. The median amount of salary loss was INR 10,000 (IQR 9000–25000). Decrease in income and work efficiency (self-perceived) was found to be 37.3% (n = 71) and 12.1% (n = 23), respectively. A total of 47 patients (37.3%) took personal leaves (median number – 17 days (IQR 14–25), and discrimination/stigma related to the COVID-19 at the workplace was faced by 22.6% of patients. Conclusion: Income and work of a substantial number of patients was affected due to COVID-19, as there was a decrease in income and work efficiency. Patients also had to take personal leaves and face stigma in the workplace. This will inform the policymakers to formulate strategies to mitigate the impact of COVID-19.


  • Open Access

    Response to: COVID-19-associated mucormycosis and evolving evidence

    by R Sarda, S Swain, A Ray, N Wig

    We thank Sakthivel et al. for their useful comments on our letter on COVID-19-associated Mucormycosis (CAM). Our article, as noted by them, provides an overview of the plausible pathophysiological mechanisms and likely preponderance of CAM in India. 1


  • Open Access

    Post COVID-19 sequelae: A prospective observational study from Northern India

    by Shivdas Naik, Manish Soneja, Soumendra Haldar, Netto George Mundadan, Prerna Garg, Ankit Mittal, Devashish Desai, Praveen Kumar Trilangi, Sayan Chakraborty, Nazneen Nahar Begam, et al.

    Background Long COVID, or post-COVID-19 sequelae, is being seen in a growing number of patients reporting a constellation of symptoms, both pulmonary and extrapulmonary. Studies on COVID-19 recovered patients are scarce. Thus, there is a need to add granularity to our existing knowledge about the course and long-term effects of the infection. Aim To describe the clinical details and risk factors of post-COVID sequelae in the North Indian population. Method This prospective observational study was conducted at a tertiary healthcare centre in Northern India between October 2020 to February 2021. Patients aged >18 years with a confirmed COVID-19 disease were recruited after at least two weeks of diagnosis and interviewed for any post-COVID-19 symptoms. Results Of 1234 patients recruited, who were followed up for a median duration of 91 days (IQR: 45-181 days), 495 (40.11%) patients had symptoms. In 223 (18.1%) patients, the symptoms resolved within four weeks, 150 (12.1%) patients had symptoms till twelve weeks, and 122 (9.9%) patients had symptoms beyond twelve weeks of diagnosis of COVID-19. Most common long COVID-19 symptoms included myalgia (10.9%), fatigue (5.5%), shortness of breath (6.1%), cough (2.1%), disturbed sleep (1.4%), mood disturbances (0.48%) and anxiety (0.6%). The major determinants of developing post-COVID-19 symptoms in the patients were hypothyroidism and the severity of the disease. Conclusion Most often, patients complain of myalgias, fatigue, dyspnoea, cough and disturbed sleep. Patients who are hypothyroid or have recovered from moderate to severe COVID-19 are at higher risk of developing post-COVID sequelae. Therefore, a multidisciplinary approach is required to diagnose and manage COVID-19 recovered patients.


  • Open Access

    COVID-19-associated mucormycosis: an epidemic within a pandemic

    by R Sarda, S Swain, A Ray, Naveet Wig

    India continues to battle the second wave of COVID-19 and has recently reported the highest number of cases ever in a single day from a country. As severe COVID-19 continues to claim thousands of lives in this country, there has also been a recent spate of COVID-19-associated mucormycosis (CAM) cases which have garnered attention globally. More than 14 000 cases of CAM have been reported from all over India with many states resorting to declaration of an epidemic as well as making it a notifiable disease. 1 We wish to elaborate on the evolving situation of CAM in India with special attention to the association of mucormycosis with COVID-19, the pathophysiological basis for CAM, likely reasons for preponderance of CAM in India as well as the core management issues.